+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Immunoglobulin Product Market - Global Forecast 2026-2032- Product Image
Immunoglobulin Product Market - Global Forecast 2026-2032- Product Image
New

Immunoglobulin Product Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 194 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 4904902
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The immunoglobulin product market is entering a period of accelerated transformation, requiring leaders to adapt strategies across procurement, manufacturing, and commercialization for sustained competitive advantage. As technological, supply chain, and regulatory forces intersect, executive decision-making must be anchored in robust market intelligence.

Market Snapshot: Immunoglobulin Product Market Growth and Outlook

The immunoglobulin product market is witnessing significant expansion. Market value increased from USD 21.31 billion in 2025 to USD 24.00 billion in 2026, with expectations of reaching USD 50.29 billion by 2032, supported by a compound annual growth rate of 13.04%. Key growth drivers include advances in therapeutic innovation, evolving clinical protocols, and changing global procurement models. These trends are prompting higher demand, increasingly diversified sourcing, and new imperatives for supply chain resilience and responsive delivery. As clinical best practices evolve, procurement strategies and commercial operations must adapt to ever-shifting patient needs and regulatory frameworks.

Scope & Segmentation: Strategic Overview of Market Dynamics

  • Source Materials: Pooled human plasma remains the principal source, while recombinant modalities are emerging, both influencing manufacturing scale, pathogen safety, and supply reliability.
  • Product Types: Standard immunoglobulin and hyperimmune preparations serve broad and targeted therapy needs, each with unique clinical and commercial pathways.
  • Routes of Administration: Intravenous, subcutaneous, and intramuscular options determine workflow efficiency, patient access models, and have cost implications for health systems and providers.
  • Clinical Applications: Treatments span hematological, infectious, neurological, and primary immune deficiency conditions, necessitating specific infusion protocols and robust evidence bases.
  • Regions: Americas feature advanced infrastructure and fractionation capacity; EMEA presents diverse regulatory environments and partnerships; Asia-Pacific is rapidly expanding healthcare access, with increased manufacturing activity and policy support.
  • Enabling Technologies: Innovations in recombinant engineering, fractionation science, modular manufacturing, and viral safety are enhancing process efficiency, compliance, and the ability to scale regionally or globally.

Key Takeaways: Insights for Senior Decision-Makers

  • Broader therapeutic adoption is accelerating the use of both standard and hyperimmune immunoglobulin, as administration models shift toward more ambulatory and home-based settings.
  • Diversification of source material and investments in regional manufacturing are essential to reduce reliance on donors, supporting quicker adaptation to evolving clinical and supply needs.
  • Tightening regulations on donor screening and safety are driving industry uptake of advanced viral reduction and tracking tools, leading to shifts in both sourcing and production strategies.
  • Commercial models increasingly prioritize value-based procurement and evidence generation, enabling outcomes-focused contracts and improved payer engagement for long-term sustainability.
  • Supply chain strategies now require nearshoring and supplier diversification to address rising operational complexity, ensure business continuity, and manage tariff-driven disruptions.

Impact of 2025 Tariff Policies on the Value Chain

Recent changes in tariff policies have led to notable shifts across immunoglobulin procurement and manufacturing. Rising costs are prompting organizations to renegotiate supplier relationships and consider alternative sourcing strategies, such as nearshoring or contract manufacturing. Logistics stakeholders are adapting to higher operational expenses, fostering new approaches to inventory management and scenario planning. Sector leaders now emphasize regional capacity building, rigorous risk mitigation, and collaborative agreements to support the long-term stability of the global immunoglobulin supply chain.

Methodology & Data Sources

This analysis synthesizes direct interviews with manufacturing and clinical leaders, in-depth reviews of peer-reviewed literature, and robust scenario analysis. All insights are validated through triangulation, ensuring that recommendations are both actionable and tailored to the immunoglobulin product market’s current and future dynamics.

Why This Report Matters

  • Supports senior leaders in aligning procurement, manufacturing, and commercialization strategies with evolving clinical and regulatory benchmarks across the immunoglobulin sector.
  • Enables organizations to anticipate and proactively address regulatory fluctuations, regional diversification, and supply chain complexities, reinforcing cost efficiency and secure patient access.
  • Delivers actionable pathways for scenario planning, partnership development, and evidence-based stakeholder engagement to drive resilient, sustained growth in the immunoglobulin marketplace.

Conclusion

Organizations embracing diverse sourcing, supply chain resilience, and regionally adapted commercial strategies will be well-positioned to secure future growth. Market success depends on integrating manufacturing innovation and robust scenario planning with evidence-focused leadership.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Immunoglobulin Product Market, by Product Type
8.1. Hyperimmune Globulin
8.2. Standard Immunoglobulin
9. Immunoglobulin Product Market, by Source
9.1. Pooled Human Plasma
9.2. Recombinant
10. Immunoglobulin Product Market, by Route Of Administration
10.1. Intramuscular
10.2. Intravenous
10.3. Subcutaneous
11. Immunoglobulin Product Market, by Application
11.1. Hematological Disorders
11.1.1. Hemolytic Anemia
11.1.2. Idiopathic Thrombocytopenic Purpura
11.2. Infectious Diseases
11.2.1. Hepatitis A
11.2.2. Rubella
11.2.3. Varicella
11.3. Neurological Disorders
11.3.1. Chronic Inflammatory Demyelinating Polyneuropathy
11.3.2. Guillain-Barre Syndrome
11.3.3. Myasthenia Gravis
11.4. Primary Immune Deficiency
11.4.1. Common Variable Immunodeficiency
11.4.2. Severe Combined Immunodeficiency
11.4.3. X-Linked Agammaglobulinemia
12. Immunoglobulin Product Market, by Region
12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific
13. Immunoglobulin Product Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Immunoglobulin Product Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. United States Immunoglobulin Product Market
16. China Immunoglobulin Product Market
17. Competitive Landscape
17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. ADMA Biologics, Inc.
17.6. Baxter International Inc.
17.7. Bharat Serum & Vaccines Ltd.
17.8. Bio Products Laboratory Limited
17.9. Biotest AG
17.10. China National Biotec Group
17.11. CSL Behring
17.12. Emergent BioSolutions Inc.
17.13. GC Pharma Co., Ltd.
17.14. Green Cross Corporation
17.15. Grifols, S.A.
17.16. Hualan Bioengineering Co., Ltd.
17.17. Intas Biopharmaceuticals Ltd.
17.18. Kamada Ltd.
17.19. Kamapharam
17.20. Kedrion S.p.A.
17.21. LFB Group
17.22. LFB S.A.
17.23. Octapharma AG
17.24. Omrix Biopharmaceuticals Ltd.
17.25. Sanquin Blood Supply Foundation
17.26. Shanghai RAAS Blood Products Co., Ltd.
17.27. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
17.28. Swedish Orphan Biovitrum AB
17.29. Takeda Pharmaceutical Company Limited
List of Figures
FIGURE 1. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HYPERIMMUNE GLOBULIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HYPERIMMUNE GLOBULIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HYPERIMMUNE GLOBULIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY STANDARD IMMUNOGLOBULIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY STANDARD IMMUNOGLOBULIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY STANDARD IMMUNOGLOBULIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY POOLED HUMAN PLASMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY POOLED HUMAN PLASMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY POOLED HUMAN PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMOLYTIC ANEMIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMOLYTIC ANEMIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMOLYTIC ANEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY IDIOPATHIC THROMBOCYTOPENIC PURPURA, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY IDIOPATHIC THROMBOCYTOPENIC PURPURA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY IDIOPATHIC THROMBOCYTOPENIC PURPURA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEPATITIS A, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEPATITIS A, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEPATITIS A, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY RUBELLA, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY RUBELLA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY RUBELLA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY VARICELLA, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY VARICELLA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY VARICELLA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY GUILLAIN-BARRE SYNDROME, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY GUILLAIN-BARRE SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY GUILLAIN-BARRE SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY MYASTHENIA GRAVIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY MYASTHENIA GRAVIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY MYASTHENIA GRAVIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COMMON VARIABLE IMMUNODEFICIENCY, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COMMON VARIABLE IMMUNODEFICIENCY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COMMON VARIABLE IMMUNODEFICIENCY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SEVERE COMBINED IMMUNODEFICIENCY, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SEVERE COMBINED IMMUNODEFICIENCY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SEVERE COMBINED IMMUNODEFICIENCY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY X-LINKED AGAMMAGLOBULINEMIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY X-LINKED AGAMMAGLOBULINEMIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY X-LINKED AGAMMAGLOBULINEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. AMERICAS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 78. AMERICAS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 79. AMERICAS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 80. AMERICAS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 81. AMERICAS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 82. AMERICAS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 83. AMERICAS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 84. AMERICAS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 85. AMERICAS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
TABLE 86. NORTH AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. NORTH AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 88. NORTH AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 89. NORTH AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 90. NORTH AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 91. NORTH AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 92. NORTH AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 93. NORTH AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 94. NORTH AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
TABLE 95. LATIN AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. LATIN AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 97. LATIN AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 98. LATIN AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 99. LATIN AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 100. LATIN AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 101. LATIN AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 102. LATIN AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 103. LATIN AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
TABLE 113. EUROPE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 114. EUROPE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 115. EUROPE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 116. EUROPE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 117. EUROPE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 118. EUROPE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 119. EUROPE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 120. EUROPE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 121. EUROPE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
TABLE 122. MIDDLE EAST IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 123. MIDDLE EAST IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 124. MIDDLE EAST IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 125. MIDDLE EAST IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 126. MIDDLE EAST IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 127. MIDDLE EAST IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 128. MIDDLE EAST IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 129. MIDDLE EAST IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 130. MIDDLE EAST IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
TABLE 131. AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 132. AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 133. AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 134. AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 135. AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 136. AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 137. AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 138. AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 139. AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
TABLE 140. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 141. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 142. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 143. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 144. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 145. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 146. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 147. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 148. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
TABLE 149. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 150. ASEAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 151. ASEAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 152. ASEAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 153. ASEAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 154. ASEAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 155. ASEAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 156. ASEAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 157. ASEAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 158. ASEAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
TABLE 159. GCC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 160. GCC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 161. GCC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 162. GCC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 163. GCC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 164. GCC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 165. GCC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 166. GCC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 167. GCC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
TABLE 168. EUROPEAN UNION IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 169. EUROPEAN UNION IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 170. EUROPEAN UNION IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 171. EUROPEAN UNION IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 172. EUROPEAN UNION IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 173. EUROPEAN UNION IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 174. EUROPEAN UNION IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 175. EUROPEAN UNION IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 176. EUROPEAN UNION IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
TABLE 177. BRICS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 178. BRICS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 179. BRICS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 180. BRICS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 181. BRICS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 182. BRICS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 183. BRICS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 184. BRICS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 185. BRICS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
TABLE 186. G7 IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 187. G7 IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 188. G7 IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 189. G7 IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 190. G7 IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 191. G7 IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 192. G7 IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 193. G7 IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 194. G7 IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
TABLE 195. NATO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 196. NATO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 197. NATO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 198. NATO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 199. NATO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 200. NATO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 201. NATO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 202. NATO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 203. NATO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
TABLE 204. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 205. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 206. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 207. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 208. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 209. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 210. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 211. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 212. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 213. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
TABLE 214. CHINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 215. CHINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 216. CHINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 217. CHINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 218. CHINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 219. CHINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 220. CHINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 221. CHINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 222. CHINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Immunoglobulin Product market report include:
  • ADMA Biologics, Inc.
  • Baxter International Inc.
  • Bharat Serum & Vaccines Ltd.
  • Bio Products Laboratory Limited
  • Biotest AG
  • China National Biotec Group
  • CSL Behring
  • Emergent BioSolutions Inc.
  • GC Pharma Co., Ltd.
  • Green Cross Corporation
  • Grifols, S.A.
  • Hualan Bioengineering Co., Ltd.
  • Intas Biopharmaceuticals Ltd.
  • Kamada Ltd.
  • Kamapharam
  • Kedrion S.p.A.
  • LFB Group
  • LFB S.A.
  • Octapharma AG
  • Omrix Biopharmaceuticals Ltd.
  • Sanquin Blood Supply Foundation
  • Shanghai RAAS Blood Products Co., Ltd.
  • Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
  • Swedish Orphan Biovitrum AB
  • Takeda Pharmaceutical Company Limited

Table Information

Report AttributeDetails
No. of Pages194
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 24 Billion
Forecasted Market Value ( USD ) by 2032 $ 50.29 Billion
Compound Annual Growth Rate13.0%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Subcutaneous Immunoglobulin Market - Global Forecast 2026-2032 - Product Image

Subcutaneous Immunoglobulin Market - Global Forecast 2026-2032

  • Report
  • 188 Pages
  • Global
From
Immunoglobulin Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Immunoglobulin Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Immunoglobulin Market Size, Share, Trends and Forecast by Product, Application, Mode of Delivery, and Region, 2025-2033 - Product Image

Immunoglobulin Market Size, Share, Trends and Forecast by Product, Application, Mode of Delivery, and Region, 2025-2033

  • Report
  • 149 Pages
  • Global
From
Intravenous Immunoglobulin Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Intravenous Immunoglobulin Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Intravenous Immunoglobulin Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Intravenous Immunoglobulin Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From

About the Immunoglobulin Market

The Immunoglobulin market is a segment of the Immune Disorders Drugs market, which focuses on treatments for conditions related to the immune system. Immunoglobulin (Ig) is a type of protein found in the blood that helps fight infection and disease. It is used to treat a variety of immune-related conditions, including autoimmune diseases, allergies, and infections. Immunoglobulin therapies are typically administered intravenously or subcutaneously, and can be used to replace or supplement the body's natural Ig production. The Immunoglobulin market is highly competitive, with a number of companies offering a range of products. These products vary in terms of dosage, delivery method, and cost. Companies in the market are focused on developing new therapies and improving existing ones, as well as expanding their product portfolios. Some of the major companies in the Immunoglobulin market include CSL Behring, Grifols, Kedrion, Octapharma, and Shire. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.